Abstract:

Objective: To explore the correlation between the expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in prostate cancer (PCa) and its clinicopathological data including tumor grade and clinical stage. Methods: The expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin was examined in 157 cases of PCa and adjacent normal prostatic tissue by immunohistochemical assay, and the correlation with clinicopathological features was analyzed. Results: Expressions of α5-integrin, α7-integrin, and Ε-cadherin in PCa were lower than those in normal prostatic tissues (P<0.05). N-cadherin expression was higher in cancer prostatic tissue than in normal prostatic tissues (P<0.05). The reduced expression of α5-integrin, α7-integrin, and Ε-cadherin was related to Gleason score, pathological stage, lymph node metastasis, and prostate-specific antigen level, but it was not associated with positive surgical margins and patient age. The increased expression of N-cadherin was related to Gleason score, pathological stage, lymph node metastasis, and prostate-specific antigen level, but not to age and positive surgical margins. The expression of E-cadherin was highly negatively correlated with that of N-cadherin and also positively correlated with that of α5-integrin and α7-integrin. Conclusion: The reduced expression of α5-integrin, α7-integrin, and Ε-cadherin and abnormal expression of N-cadherin play an important role in the occurrence and development of PCa. The results indicate that these have potential values in the diagnosis and are predictable indices in the proliferation of PCa. © 2016 Elsevier Inc.

Notes:

Cited By :2Export Date: 18 February 2017References: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012 (2012) CA Cancer J Clin, 62, pp. 10-29;Chrisofos, M., Papatsoris, A.G., Lazaris, A., Deliveliotis, Precursor lesions of prostate cancer (2007) Crit Rev Clin Lab Sci, 44, pp. 243-270; Reynolds, M.A., Kastury, K., Groskopf, J., Schalken, J.A., Rittenhouse, H., Molecular markers for prostate cancer (2007) Cancer Lett, 249, pp. 5-13; Bauer, J.J., Connelly, R.R., Seterhenn, I.A., Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer (1998) J Urol, 159, pp. 929-933; Borre, M., Hoyer, M., Nerstrom, B., DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure (1998) Prostate, 36, pp. 244-249; Cheng, L., Jones, T.D., Lin, H., Eble, J.N., Zeng, G., Carr, M.D., Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma (2005) J Urol, 174, pp. 2181-2185; Drivalos, A., Papatsoris, A.G., Chrisofos, M., Efstathiou, E., Dimopoulos, M.A., The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer (2011) Int Braz J Urol, 37, pp. 302-306; Lascombe, I., Clairotte, A., Fauconnet, S., Bernardini, S., Wallerand, H., Kantelip, B., N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors (2006) Clin Cancer Res, 12, pp. 2780-2787; Hirohashi, S., Kanai, Y., Cell adhesion system and human cancer morphogenesis (2003) Cancer Sci, 94, pp. 575-581; Rhodes, D.R., Sanda, M.G., Otte, A.P., Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer (2003) J Natl Cancer Inst, 95, pp. 661-668; Ashida, K., Terada, T., Kitamura, Y., Kaibara, N., Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study (2008) Hepatology, 27, pp. 974-982; Rakha, E.A., Abd El Rehim, D., Pinder, S.E., Lewis, S.A., Ellis, I.O., E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance (2005) Histopathology, 46, pp. 685-693; Huiping, C., Kristjansdottir, S., Jonasson, J.G., Magnusson, J., Egilsson, V., Ingvarsson, S., Alterations of E-cadherin and beat-catenin in gastric cancer (2012) BNC Cancer, 1, pp. 16-25; Endo, K., Ueda, T., Ueyama, J., Ohta, T., Terada, T., Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients[U+05F3] survival (2010) Hum Pathol, 31, pp. 558-565; Elzagheid, A., Algars, A., Bendardaf, R., Lamlum, H., Ristamaki, R., Collan, Y., E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome (2006) World J Gastroenterol, 12, pp. 4304-4309; Pontes-Junior, J., Reis, S.T., Dall'Oglio, M., Neves de Oliveira, L.C., Cury, J., Carvalho, P.A., Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer (2009) J Carcinog, 8, p. 3; Liu, G.L., Yang, H.J., Liu, T., Lin, Y.Z., Expression and significance of E-cadherin, N-cadherin, transforming growth factor-β1 and Twist in prostate cancer (2014) Asian Pac J Trop Med, 7, pp. 76-82; De Marzo, A.M., Knudsen, B., Chan-Tack, K., E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens (1999) Urology, 53, pp. 707-713; Ke, X.S., Goldfinger, N., Rostad, K., Hovland, R., Akslen, L.A., Rotter, V., Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation (2008) PLoS One, 3; Wang, H.Y., Chen, Z., Wang, Z.H., Wang, H., Huang, L.M., Prognostic significance of α5β1-integrin expression in cervical cancer (2013) Asian Pac J Cancer Prev, 14, pp. 3891-3895; Fang, Z., Yao, W., Xiong, Y., Zhang, J., Liu, L., Li, J., Functional elucidation and methylation-mediated downregulation of ITGA5 gene in breast cancer cell line MDA-MB-468 (2010) J Cell Biochem, 110, pp. 1130-1141; Walter, R.B., Laszlo, G.S., Alonzo, T.A., Gerbing, R.B., Levy, S., Fitzgibbon, M.P., Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children[U+05F3]s Oncology Group (2013) Am J Hematol, 88, pp. 694-702; Hsia, H.C., Nair, M.R., Corbett, S.A., The fate of internalized α5 integrin is regulated by matrix-capable fibronectin (2014) J Surg Res, 191 (2), pp. 268-279; Ren, B.1., Yu, Y.P., Tseng, G.C., Wu, C., Chen, K., Rao, U.N., Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma (2007) J Natl Cancer Inst, 99, pp. 868-880; Jaggi, M.1., Nazemi, T., Abrahams, N.A., Baker, J.J., Galich, A., Smith, L.M., N-cadherin switching occurs in high Gleason grade prostate cancer (2006) Prostate, 66, pp. 193-199; Gravdal, K.1., Halvorsen, O.J., Haukaas, S.A., Akslen, L.A., A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer (2007) Clin Cancer Res, 13, pp. 7003-7011; Hazan, R.B., Qiao, R., Keren, R., Badano, I., Suyama, K., Cadherin switch in tumor progression (2004) Ann N Y Acad Sci, 1014, pp. 155-163; Nadler, R.B., Loeb, S., Roehl, K.A., Antenor, J.A., Catalona, W.J., Suarez, B.K., Use of 2.6 ng/mL prostate specific antigen prompt for biopsy in men older than 60 years (2005) J Urol, 174, p. 21542157; Jaggi, M.1., Johansson, S.L., Baker, J.J., Smith, L.M., Galich, A., Balaji, K.C., Aberrant expression of E-cadherin and beta-catenin in human prostate cancer (2005) Urol Oncol, 23, pp. 402-406

Website